Previous Close | 56.16 |
Open | 56.13 |
Bid | 59.00 |
Ask | 63.85 |
Strike | 175.00 |
Expire Date | 2025-01-17 |
Day's Range | 56.13 - 56.16 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
PBH vs. ABT: Which Stock Is the Better Value Option?
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.